3-氯二苯甲胺 | 55095-14-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氯二苯甲胺
• 中文别名: 间氯二苯甲胺
• 英文名称: 3-Chlor-benzhydrylamin
• 英文别名: [1-phenyl-1-(3-chlorophenyl)methyl]amine；(3-Chlorophenyl)(phenyl)methanamine；(3-chlorophenyl)-phenylmethanamine
• CAS: 55095-14-2
• 化学式: C₁₃H₁₂ClN
• 分子量: 217.698
• InChiKey: LAYKXXDKBWCIFM-UHFFFAOYSA-N

物化性质

• 沸点：
  327.8±27.0 °C(Predicted)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-氯二苯甲胺 在 N-甲基吗啉 、 盐酸 、 氯甲酸异丁酯 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 3.08h， 生成
  参考文献：
  名称：

  Synthesis and structure–activity relationships of potential anticonvulsants based on 2-piperidinecarboxylic acid and related pharmacophores

  摘要：

  Using N-(2,6-dimethyl)phenyl-2-piperidinecarboxamide (1) and N-(alpha -methylbenzyl)-2-piperidinecarboxamide (2) as structural leads, a variety of analogues were synthesised and evaluated for anticonvulsant activity in the MES test in mice. In the N-benzyl series, introduction of 3-Cl, 4-Cl, 3,4-Cl-2, or 3-CF3 groups on the aromatic ring led to an increase in MES activity. Replacement of the alpha -methyl group by either i-Pr or benzyl groups enhanced MES activity with no increase in neurotoxicity. Substitution on the piperidine ring nitrogen led to a decrease in MES activity and neurotoxicity, while reduction of the amide carbonyl led to a complete loss of activity. Movement of the carboxamide group to either the 3- or 4-positions of the piperidine ring decreased MES activity and neurotoxicity. Incorporation of the piperidine ring into a tetrahydroisoquinoline or diazahydrinone nucleus led to increased neurotoxicity. In the N-(2,6-dimethyl)phenyl series, opening of the piperidine ring between the 1- and 6-positions gave the active norleucine derivative 75 (ED50 = 5.8 mg kg(-1), TD50 = 36.4 mg kg(-1), PI = 6.3). Replacement of the piperidine ring of I by cycloalkane (cyclohexane, cyclopentane, and cyclobutane) resulted in compounds with decreased MES activity and neurotoxicity, whereas replacement of the piperidine ring by a 4-pyridyl group led to a retention of MES activity with a comparable PI. Simplification of the 2-piperidinecarboxamide nucleus of 1 into a glycinecarboxamide nucleus led to about a six-fold decrease in MES activity. The 2,6-dimethylanilides were the most potent compounds in the MES test in each group of compounds evaluated, and compounds 50 and 75 should be useful leads in the development of agents for the treatment of tonic-clonic and partial seizures in man. (C) 2001 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(00)01206-x
• 作为产物：
  描述：

  N-(m-chlorobenzhydryl)formamide 在 盐酸 作用下， 反应 1.0h， 生成 3-氯二苯甲胺
  参考文献：
  名称：

  Synthesis and structure–activity relationships of potential anticonvulsants based on 2-piperidinecarboxylic acid and related pharmacophores

  摘要：

  Using N-(2,6-dimethyl)phenyl-2-piperidinecarboxamide (1) and N-(alpha -methylbenzyl)-2-piperidinecarboxamide (2) as structural leads, a variety of analogues were synthesised and evaluated for anticonvulsant activity in the MES test in mice. In the N-benzyl series, introduction of 3-Cl, 4-Cl, 3,4-Cl-2, or 3-CF3 groups on the aromatic ring led to an increase in MES activity. Replacement of the alpha -methyl group by either i-Pr or benzyl groups enhanced MES activity with no increase in neurotoxicity. Substitution on the piperidine ring nitrogen led to a decrease in MES activity and neurotoxicity, while reduction of the amide carbonyl led to a complete loss of activity. Movement of the carboxamide group to either the 3- or 4-positions of the piperidine ring decreased MES activity and neurotoxicity. Incorporation of the piperidine ring into a tetrahydroisoquinoline or diazahydrinone nucleus led to increased neurotoxicity. In the N-(2,6-dimethyl)phenyl series, opening of the piperidine ring between the 1- and 6-positions gave the active norleucine derivative 75 (ED50 = 5.8 mg kg(-1), TD50 = 36.4 mg kg(-1), PI = 6.3). Replacement of the piperidine ring of I by cycloalkane (cyclohexane, cyclopentane, and cyclobutane) resulted in compounds with decreased MES activity and neurotoxicity, whereas replacement of the piperidine ring by a 4-pyridyl group led to a retention of MES activity with a comparable PI. Simplification of the 2-piperidinecarboxamide nucleus of 1 into a glycinecarboxamide nucleus led to about a six-fold decrease in MES activity. The 2,6-dimethylanilides were the most potent compounds in the MES test in each group of compounds evaluated, and compounds 50 and 75 should be useful leads in the development of agents for the treatment of tonic-clonic and partial seizures in man. (C) 2001 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(00)01206-x

文献信息

• [EN] BROAD-SPECTRUM INHIBITORS OF FILOVIRUSES<br/>[FR] INHIBITEURS À LARGE SPECTRE DE FILOVIRUS
  申请人：MICROBIOTIX INC

  公开号：WO2018106667A1

  公开（公告）日：2018-06-14

  The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of filovirus infection in humans and other mammals. A new class of small molecules is disclosed that inhibits the interaction of naturally processed (i.e., proteolytically cleaved) filovirus glycoprotein (GPCL) with its host receptor Niemann-Pick C 1 (NPCl) protein and thus block infection of host cells by filoviruses. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of filovirus infection.

  本发明涉及开发用于治疗和/或预防人类和其他哺乳动物的Filovirus感染的治疗和预防剂。揭示了一类新的小分子，它抑制了自然加工（即蛋白酶水解）的Filovirus糖蛋白（GPCL）与其宿主受体Niemann-Pick C1（NPC1）蛋白的相互作用，从而阻止Filovirus感染宿主细胞。还揭示了在治疗/预防Filovirus感染中使用小分子抑制剂的方法。
• SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES
  申请人：Bissantz Caterina

  公开号：US20080171759A1

  公开（公告）日：2008-07-17

  In particular, the present invention is concerned with compounds of the general formula (I) wherein X, Y and R 1 to R 10 are as described herein. The compounds are V1a receptor antagonists. The invention also relates to the manufacture of compounds of formula I, pharmaceutical compositions containing them and their use for the treatment of anxiety and depressive disorders and other diseases.

  具体而言，本发明涉及一般式（I）中的化合物，其中X、Y和R1至R10如本文所述。这些化合物是V1a受体拮抗剂。该发明还涉及制备一般式I的化合物、含有它们的药物组合物以及它们用于治疗焦虑和抑郁症等疾病的用途。
• 旋光异构体：(+)-二苯甲基脲和(-)-二苯甲基脲以及(+)-1-[（3-氯苯基)-苯基-甲基]脲和(-)-1-[（3-氯苯基)-苯基-甲基]脲，它们的药物制剂及其制备方法
  申请人：辛泰格有限公司

  公开号：CN105392775A

  公开（公告）日：2016-03-09

  本发明涉及一种新的物质，尤其涉及一种旋光异构体：由通式(I)所示的(+)-二苯甲基脲和(-)-二苯甲基脲，以及(+)-1-[(3-氯苯基)-苯基-甲基]脲和(-)-1-[(3-氯苯基)-苯基-甲基]脲,基于它们的药物组合物，以及所述旋光异构体的制备方法和基于它们所表现出的不同治疗功效的应用。(I)其中，R≠Rˊ，并且选自以下基团：氢，烷基，卤素，硝基，氨基，烷氨基和羟基，并且处于苯环的邻位、对位或间位。当外消旋的Halodif？1-[(3-氯苯基)-苯基-甲基]脲采用本发明所述的方法进行分离时，得到了具有不同程度治疗效果的(+)-和(-)-1-[(3-氯苯基)-苯基-甲基]脲的旋光异构体。
• The determination of enantiomer composition of 1-((3-chlorophenyl)-(phenyl)methyl) amine and 1-((3-chlorophenyl)(phenyl)-methyl) urea (Galodif) by NMR spectroscopy, chiral HPLC, and polarimetry
  作者：Vera Yu. Kuksenok、Victoria V. Shtrykova、Victor D. Filimonov、Alexandr G. Druganov、Alexandr A. Bondarev、Ksenia S. Stankevich

  DOI：10.1002/chir.23005

  日期：2018.10

  For the first time, a method for enantiomer resolution of the anticonvulsant Galodif (1‐((3‐chlorophenyl)(phenyl)methyl) urea) by chiral HPLC was developed, whereas the enantiomeric composition of 1‐((3‐chlorophenyl)(phenyl)methyl) amine—precursor in Galodif synthesis—cannot be resolved by this method. However, starting 1‐((3‐chlorophenyl)(phenyl)methyl) amine quantitatively forms diastereomeric N

  首次开发了一种通过手性HPLC拆分抗惊厥性Galodif（1-（（（3-氯苯基）（苯基）甲基）尿素）的对映体的方法，而1-（（（3-氯苯基）] [苯）甲基）胺-Galodif合成中的前体-无法通过这种方法拆分。但是，与手性（1 R）-（+）反应时，起始1-（（3-氯苯基）（苯基）甲基）胺定量形成非对映异构N -（（3-氯苯基）（苯基）甲基）-1-樟脑磺酰胺。或（1 S）-（-）-樟脑10-磺酰氯。所得樟脑磺酰胺的非对映异构体比例可以通过NMR 1 H和13轻松确定C光谱。DFT计算的加洛迪夫对映体比旋光度与实验数据吻合良好。对映异构体的绝对构型是首次提出。
• OPTICAL ISOMERS OF (+) AND (-)-BENZHYDRYL UREAS AND (+) AND (-)-1-[(3-CHLOROPHENYL)-PHENYL-METHYL] UREA, A PHARMACEUTICAL COMPOSITION BASED THEREON AND A METHOD FOR PRODUCING SAID OPTICAL ISOMERS
  申请人：OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOSTIYU "SINTEGAL"

  公开号：US20160244404A1

  公开（公告）日：2016-08-25

  The invention relates to novel substances, and more particularly to optical isomers of (+) and (−)-benzhydryl ureas of formula (I) and (+) and (−)-1-[(3-chlorophenyl)-phenyl-methyl]urea, a pharmaceutical composition based thereon, and a method for producing said optical isomers and for using same on the basis of the different therapeutic activity exhibited. (I) Where R≠R′ and are selected from the group comprising hydrogen, alkyl, halogen, nitro, amino, alkylamino and hydroxy groups and are situated in the ortho-, para- or meta-positions of the benzene rings. When racemic Halodif 1-[(3-chlorophenyl)-phenyl-methyl]urea was separated using the method according to the invention, optical isomers of (+) and (−)-1-[(3-chlorophenyl)-phenyl-methyl]urea (Halodif isomers) with different degrees of therapeutic activity were produced.

  该发明涉及新颖物质，更具体地涉及公式（I）中的光学异构体以及基于此的药物组合物和生产该光学异构体的方法，以及基于展示的不同治疗活性使用它们的方法。其中R≠R′，并且选自包括氢、烷基、卤素、硝基、氨基、烷基氨基和羟基的基团，并位于苯环的邻位、对位或间位。当使用该发明的方法分离混合的1-[(3-氯苯基)-苯基甲基]脲的外消旋体时，产生了具有不同治疗活性程度的光学异构体（Halodif异构体）。